Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.

Neoplasia (New York, N.Y.) - 1 Mar 2017

Paasinen-Sohns Aino, Koelzer Viktor H, Frank Angela, Schafroth Julian, Gisler Aline, Sachs Melanie, Graber Anne, Rothschild Sacha I, Wicki Andreas, Cathomas Gieri, Mertz Kirsten D

Abstract excerpt

Companion diagnostics rely on genomic testing of molecular alterations to enable effective cancer treatment. Here we report the clinical application and validation of the Oncomine Focus Assay (OFA), an integrated, commercially available next-generation sequencing (NGS) assay for the rapid and simultaneous detection of single nucleotide variants, short insertions and deletions, copy number variations, and gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Immunohistochemistry

Share to Melanoma

Share to Neoplasms

Share to Reproducibility of Results

Source

Open in PubMed Open full text

Identifiers

PMID: 28161563
DOI: 10.1016/j.neo.2017.01.003
PMCID: PMC5293722

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.PMID 28161563Read ↗

Advantages of MelArray over Oncomine Focus Assay for Mutation Analysis in Melanoma.Semantic proximity Read ↗

Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging ApplicationsSemantic proximity Read ↗

A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumoursSemantic proximity Read ↗

Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.Semantic proximity Read ↗

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.Semantic proximity Read ↗

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.Semantic proximity Read ↗

Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors.Semantic proximity Read ↗

Implementation of an ISO 15189 accredited next generation sequencing service for cell-free total nucleic acid (cfTNA) analysis to facilitate driver mutation reporting in blood: the experience of a clinical diagnostic laboratorySemantic proximity Read ↗

Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology.Semantic proximity Read ↗

Validation of a next-generation sequencing assay for clinical molecular oncology.Semantic proximity Read ↗

Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.Semantic proximity Read ↗

Technical feasibility of a long read, fourth generation sequencing platform in diagnostic profiling of clinical routine samples: a proof-of-concept study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.